Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study - Quiz - MDSpire

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • By

  • Lili Cheng

  • Dong Liang

  • Jing Jia

  • Runfeng Zhang

  • Yang Yang

  • Peng Liu

  • Hongli Sun

  • Xiaoqi Qin

  • Yanping Ma

  • Yin Wu

  • Hua Wang

  • Junling Zhuang

  • March 10, 2026

  • 0 min

Share

Original Source(s)

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • by Lili Cheng, Dong Liang, Jing Jia, Runfeng Zhang, Yang Yang, Peng Liu, Hongli Sun, Xiaoqi Qin, Yanping Ma, Yin Wu, Hua Wang, Junling Zhuang

  • March 10, 2026

Related Content

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders